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Background: The NCI-MATCH trial is the largest national study (1173 sites) for pts
with relapsed/ refractory solid tumors, lymphomas andmyeloma, which assigns tar-
geted therapies based on individual tumor molecular alterations detected using the
adapted Oncomine AmpliSeq panel (143 genes) and immunohistochemistry (IHC).
We hypothesized that patients with PTEN-deficient cancers enrolled to Arms N and P
may benefit from treatment with the PI3K beta-selective inhibitor GSK2636771.
Methods: Eligibility: relapsed/refractory ca, good end-organ function, and ECOG
PS 1. Pts were screened for molecular alterations by centralized testing on fresh
tumor biopsy and had deleterious PTENmut/del without loss of expression (ArmN)
or complete loss of cytoplasmic and nuclear PTEN staining on IHC (Arm P), and no
other aberrations activating the PI3K/MTOR andMAPK pathways (mut in PIK3CA,
PIK3R1, BRAF, KRAS, AKT1, TSC1/2, mTOR, RHEB, NF2, NRAS, HRAS). Pts
received GSK2636771 400mg/day (28-days cycles). RECIST 1.1 overall response rate
(ORR) was the primary endpoint.
Results:Of 59 enrolled pts, 56 were eligible and received treatment. Of 22 pts with
PTENmut/del (ArmN: 6 uterine, 2 breast, 2 prostate, 2 head/neck ca, 10 other), all are
off treatment as of analysis (14 disease progression, 4 for adverse events [AEs], 4 other).
One pt (4.5%) with prostate ca (PTEN deletion, MPRSS2-ERG fusion) attained a par-
tial response (-42%). Of 7 (32%) pts with stable disease (SD), 2 had SD> 6months
(uterine leiomyosarcoma; endometrial carcinoma). Of 34 pts with loss of PTEN protein
by IHC (Arm P: 7 prostate, 6 breast, 3 squamous anal ca, 2 cholangiocarcinoma, 16
other), all are off treatment as of analysis (26 disease progression, 4 for AE, 4 other). Of
9 (37.5%) pts with SD, 3 had SD> 6months (prostate cancer; squamous bladder can-
cer, squamous anal cancer). Median progression-free survival was 1.8 months for both
arms. Gr 3 treatment-related (tr) reversible toxicities were experienced by 30% (7)
and 20% (7) of pts in arms N and P, respectively. No tr Gr 5 toxicities were observed in
either arm.
Conclusions: Single agent GSK2636771 has very modest activity in ca with PTEN gene
mutation/deletion and/or PTEN protein loss.
Clinical trial identification:NCT02465060.
Legal entity responsible for the study:NCI ECOG-ACRIN.
Funding:NCI ECOG-ACRIN.
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Background: In this era of personalized medicine there is outburst of information and
plethora of new treatment strategy. Data Tsunami overwhelms human cognitive
capacity. Artificial intelligence is being used for information-intensive decisionmaking.
We present here an experience with this technology in cancer treatment decision
support.
Methods:WFOwas used to obtain treatment recommendations of cases that were pre-
viously evaluated by aMDT at amajor cancer center in India between 2014 and 2016. A
comparison was made between the oncology advisor’s recommended treatment and
that of the tumor board. Treatment concordance was defined as a tumor board recom-
mendation falling into the oncology advisor’s categories of "recommended" or "for
consideration" treatments. All non-concordant cases (n¼ 33) were re-presented to the
tumor board in a blinded fashion in 2016 to address time of evaluation differences
between the tumor board and the oncology advisor. Results are presented as the pro-
portion of concordant cases.
Results: From 2014-2016 we had 126 colon cancers & 124 rectal cancers. Of colon 62 &
64 were non-metastatic &metastatic respectively, whereas in rectal cancer it was 93 &
31 respectively. Mean age of the patient was 55 years. The overall concordance at first
analysis was 87%. At sub group analysis in colon (85% vs 77%) & rectum (97%vs81%)
&Overall (92% vs78%) non-metastatic cases had higher concordance level thanmeta-
static cases (Table1). There were 31 cases which were non-concordant that were re-
challenged toMDT. After second review the overall concordance level improved from
87% to 95%.
Conclusions: Artificial intelligence treatment recommendations withWatson for
Oncology showed high levels of concordance with a multidisciplinary tumor board.
This cognitive computing technology holds much promise in helping oncologists make
information intensive, evidence based treatment decisions.These findings are encour-
aging for the use of this technology. Additional investigations are needed to understand
concordance in settings where cancer expertise and treatment options may differ.
Legal entity responsible for the study: Ethics Board Committee, Manipal Hospitals
Bangalore.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
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Background:ODM-203 is an orally available small molecule with balanced inhibitory
effects on FGFR 1-4 and VEGFR 1-3 subtypes. We present here results of the phase 1/2
KIDES study.
Methods: The KIDES study is an open-label, non-randomized, multicentre phase 1/2
first-in-man study of ODM-203 in patients with advanced solid tumors. In the Part 1
dose escalation (3þ 3), ODM-203 was evaluated in 31 patients between 50-800mg daily
with food to identify the maximum tolerated dose (MTD). Part 2 expansion included
53 patients to evaluate a new formulation, the recommended phase 2 dose and the dose
schedule. Patients continued ODM-203 treatment until disease progression or dose
limiting toxicity.
Results: 84 patients (median 57 years, range 28-80), with the most common tumor
types being cholangio, breast, colorectal, endometrium, ovarian and thyroid carci-
noma, were included, with most patients in Part 2 having FGFR alterations. Six patients
remain on treatment. In the dose-escalation Part 1, 800mg/day was considered the
highest dose that could not be tolerated althoughMTDwas not formally identified.
This was because of a general adverse event (AE) burden and increased bilirubin in
most patients. Bilirubin increase was due to UGT1A1 inhibition by ODM-203 and
resolved in all cases upon dose reduction/interruption. In Part 2, the optimal dose was
determined to be 400mg/day with food. Most AE’s were grade 1-2, the most common
ones being increased bilirubin (76%), fatigue and asthenia (68%), diarrhoea (60%),
stomatitis (41%), arthralgia (41%) and decreased apetite (41%). Most common grade
>3 AE’s were bilirubin increase (45%), fatigue (6%) and diarrhoea (6%). There were 6
(9%) partial responses (PR) and additionally 24 (35%) patients achieved target lesion
reduction. In total, 30 (44%) patients had disease stabilisation (SD) with median of 21
weeks on the study. The clinical benefit rate (CRþ PRþ SD) was 36/69 (52%).
Conclusions: Patients treated with ODM-203, especially those with FGFR-aberrant or
VEGFR sensitive tumours, had preliminary promising anti-tumour response and on-
target effects.
Clinical trial identification:NCT02264418.
Legal entity responsible for the study:Orion Corporation Orion Pharma.
Funding:Orion Corporation Orion Pharma.
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